Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOS | P01100 | 2/20 | 0.44 |
| ▸ | JUN | P05412 | 2/20 | 0.44 |
| ▸ | ELANE | P08246 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2969937 | 0.91 | JUN (0.43) | FOSJUNALDH1A1TSHRMAPT | |
| SCHEMBL2954382 | 0.82 | JUN (0.43) | FOSJUNALDH1A1TSHRMAPT | |
| SCHEMBL2968525 | 0.82 | ALDH1A1 (0.44) | FOSJUNALDH1A1TSHRMAPT | |
| SCHEMBL2968551 | 0.81 | FOS (0.55) | FOSJUNELANEALDH1A1TSHR | |
| SCHEMBL2960332 | 0.80 | JUN (0.55) | FOSJUNELANEALDH1A1MAPT | |
| SCHEMBL29415001 | 0.77 | NPC1 (0.57) | ELANEALDH1A1TSHRMAPTMAPK1 | |
| SCHEMBL20496430 | 0.77 | NPC1 (0.57) | ELANEALDH1A1TSHRMAPTMAPK1 | |
| SCHEMBL29415030 | 0.73 | ELANE (0.54) | ELANEALDH1A1TSHRMAPTMAPK1 | |
| SCHEMBL20496451 | 0.73 | ELANE (0.54) | ELANEALDH1A1TSHRMAPTMAPK1 | |
| SCHEMBL4284195 | 0.73 | FOS (0.64) | FOSJUNALDH1A1TSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1445249-B1 | NOVEL BENSOPHENONE DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2012-11-07 | — | — | EP | disclosed |
| US-7772285-B2 | Benzophenone derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-20050113400-A1 | Inhibitors of transcription factor AP-1; autoimmune diseases; rheumatoid arthritis; high safety and excellent pharmacokinetics in vivo | SHUNICHI SHIOZAWA (JP) | 2005-05-26 | — | — | US | disclosed |
| EP-1445249-A1 | NOVEL BENSOPHENONE DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113400-A1 | Inhibitors of transcription factor AP-1; autoimmune diseases; rheumatoid arthritis; high safety and excellent pharmacokinetics in vivo | SP1, AP1G1, JUN | FOS 163/4885JUN 3/4885ELANE 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.